Treatment of Prostate Cancer Metastatic to the Ribs

Systemic Treatment Approach

The European Association of Urology recommends androgen suppression using bilateral orchiectomy or an LHRH agonist as the cornerstone first-line treatment for metastatic prostate cancer 1, 2, 3
When initiating LHRH agonists, administer a short-course antiandrogen to prevent disease flare from the initial testosterone surge, as recommended by the European Society for Medical Oncology 1, 2
Continue androgen suppression even if the disease progresses to castration-refractory status, according to the European Association of Urology 1, 2

For painful rib metastases, a single fraction of 8 Gy is equally effective as 10 fractions of 3 Gy for pain relief and is more cost-effective, as reported by the American Society for Radiation Oncology 1, 2, 4
Both fractionation schemes provide equivalent pain-reducing efficacy in castration-refractory disease, according to the European Society for Radiotherapy and Oncology 1, 2, 3

The National Comprehensive Cancer Network recommends intravenous bisphosphonates (e.g., pamidronate) for patients with bone pain resistant to palliative radiotherapy and conventional analgesics 1, 2, 3
Patients with castration-refractory disease should be managed in collaboration with dedicated palliative care services, as suggested by the European Association of Urology 1, 2, 3

The American Society of Clinical Oncology recommends radioisotope therapy with strontium-89 or samarium-153-EDTMP for patients with painful bone metastases from castration-refractory disease 1, 2
Radium-223 is indicated for patients with symptomatic bone metastases and no known visceral disease, as it significantly improves overall survival (median 14.9 vs 11.3 months), according to the European Association of Urology 4
Radium-223 emits high-energy alpha particles with shorter path length, reducing toxicity to adjacent tissue compared to beta-emitters, as reported by the National Cancer Institute 4
Radium-223 is well-tolerated with low rates of grade 3/4 hematologic toxicity (3% neutropenia, 6% thrombocytopenia, 13% anemia), according to the American Society of Clinical Oncology 4